Current Neuro-Oncology

Volume 28 Number 16
10 June 2026

Home > Publications > Current Neuro-Oncology > Volume 28, Year 2026 > Number 16, 10 June

Gentner B, Eoli M, Farina F, Barcella M, Capotondo A, Mazzoleni S, Brambilla V, Francavilla A, Garramone M, Carrabba MG, Ferla V, Bruno A, Alvisi G, Coltella N, Montini E, Hadadi L, Capt C, Cuccarini V, Bruzzone MG, Di Meco F, Legnani FG, Ferroli P, Acerbi F, Pallini R, D'Alessandris QG, Olivi A, Gagliardi F, Snider S, Mortini P, Patanè M, Fiocchi A, Berno V, Poliani PL, Finocchiaro G, Russo C, Ciceri F, Naldini L.
Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial.
Nat Med. 2026 Jun 1;32(6):2216-2226. doi: 10.1038/s41591-026-04419-1. PMID: 42225991. Trial registration ID: NCT03866109˰ ˍ

Himic V, Johnson ML, Ratnaparkhi A, Mayrand RC, Chandar J, Govindarajan V, Kreatsoulas DC, Jahangiri A, Gersey ZC, Aaronson DM, Komotar RJ, Ivan ME, Shah AH.
Butterfly gliomas: to biopsy or to ablate - a longitudinal cohort study.
J Neurooncol. 2026 Jun 5;178(2):44. doi: 10.1007/s11060-026-05655-8. PMID: 42243447. ˍ

Park S, Kim D, Yoon HI, Lee JH, Lim DH, Kim N, Song JH, Suh CO, Wee CW, Kim IA.
Optimal clinicogenetic criteria for post-operative re-irradiation in recurrent glioblastoma: KROG 21-02.
ESMO Open. 2026 Jun 9;11(6):107730. doi: 10.1016/j.esmoop.2026.107730. PMID: 42258967. ˍ

Parker M, Carmichael A, Lucas CG Jr, Schreck KC, Redmond KJ, Kleinberg LR, Rincon-Torroella J.
Survival after hypofractionated radiation versus standard radiation in glioblastoma by MGMT promoter methylation status and age: an analysis of the national cancer database.
J Neurooncol. 2026 Jun 9;178(2):55. doi: 10.1007/s11060-026-05612-5. PMID: 42265433˰ ˍ

Breese J, Lloyd W, Fothergill A, Djoukhadar I, Tyler A, Bullock E, Cloran K, Li K, Zhu X, Alfaifi B, Sereno T, Naveen Golchha P, McMahon A, Karabatsou K, D'Urso P, Maye H, Bailey M, Hannan C, King AT, Jackson A, Hinz R, Lewis D, Coope D.
USPIO enhanced MR imaging in CNS tumors (UMIC): a study protocol.
Nanomedicine (Lond). 2026 Jun 10;21(12):1713-1721. doi: 10.1080/17435889.2026.2681555. PMID: 42267547. Trial registration ID: NCT06572475. ˍ

Gan HK, Cher L, Inglis PL, Lwin Z, Gunjur A, Balasubramanian A, Schmidt A, Wichmann CW, Guo N, Lee ST, Thomas P, Scott FE, Shard C, Fluck K, Coombs N, Palmer J, Vail ME, Allen S, Patil A, Pal B, O'Keefe GJ, Gong SJ, Ninatti G, Day BW, Gomez GA, Janes PW, Scott AM.
A Phase 1 and Biodistribution study of Ifabotuzumab, a humanized agonistic EphA3-targeted antibody, in patients with recurrent glioblastoma.
Clin Cancer Res. 2026 Jun 10. doi: 10.1158/1078-0432.CCR-25-3608. PMID: 42268288. Trial registration ID: NCT00749638(?)˰ ˍ

Limon D, Bokstein F, Blumenthal DT, Ram Z, Grossman R.
Prospective randomized trial of tumor-treating fields with chemoradiation in newly diagnosed glioblastoma.
Neurooncol Adv. 2026 Apr 24;8(1):vdag106. doi: 10.1093/noajnl/vdag106. PMID: 42239656. Trial registration ID: NCT03869242. ˍ

Saehee J, Tsutsumi S, Hashizume A, Tan S, Yoshida K, Sugiyama N, Ueno H, Ishii H.
Primary diffuse leptomeningeal glioblastoma: Report of two cases.
Surg Neurol Int. 2026 May 8;17:272. doi: 10.25259/SNI_180_2026. PMID: 42232420. ˍ

Pillai LK, Mehta MJ, Parikh A, Dash N, Shivhare V, Shah SP, Pandya A, Singh JK, Prajapati K, Bahuguna A, Darji R.
Assessment of subventricular zone irradiation in glioblastoma patients.
Front Oncol. 2026 May 22;16:1818058. doi: 10.3389/fonc.2026.1818058. PMID: 42255216. ˍ

Chun SJ, Kim N, Lim DH, Kim JY, Wee CW, Yoon HI, Jeon SH, Kim IA, Lee JH.
Impact of salvage treatment for recurrent medulloblastoma in previously irradiated patients (KROG 23-02): A multi-institutional retrospective study.
Clin Transl Radiat Oncol. 2026 May 26;59:101197. doi: 10.1016/j.ctro.2026.101197. PMID: 42255978. ˍ

Skeie BS, Craig-Craven AR, Grüner ER, Biermann M, Riemer F, Bragstad S, Sarowar S, Behbahani M, Sleire L, Schwarzlmüller T, Goplen D, Heggdal JI, Knisely JPS, Schulder M, Eide GE, Filippi CG, Enger PØ.
Phase 1 dose-escalation trial combining sulfasalazine and stereotactic radiosurgery in patients with recurrent glioblastoma.
Redox Biol. 2026 May 30;95:104241. doi: 10.1016/j.redox.2026.104241. PMID: 42229231. Trial registration ID: NCT04205357. ˍ